TIL Therapy for Metastatic Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

April 30, 2017

Conditions
Metastatic Ovarian Cancer
Interventions
DRUG

Cyclophosphamide

Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.

DRUG

Fludarabine

Fludarabine 25 mg/m2 is administered on day -5 to day -1.

BIOLOGICAL

TIL infusion

The maximum number of expanded TILs are infused over 30-45 minutes on day 0.

DRUG

Interleukin-2

Interleukin-2 is administered as a continous i.v. infusion in a decrescendo regimen (18 MIU/m3 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU/m2 IL-2 over 24 hours followed by 4,5 MIU/m2 IL-2 over another 24 hours for three days).

Trial Locations (1)

2730

Center for Cancer Immune Therapy Dept. of Hematology/oncology, Copenhagen

All Listed Sponsors
lead

Inge Marie Svane

OTHER

NCT02482090 - TIL Therapy for Metastatic Ovarian Cancer | Biotech Hunter | Biotech Hunter